Ipsen

Ipsen is a global biopharmaceutical company focused on transformative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases.

Among the top pharmaceutical companies in the world specializing in oncology, Ipsen seeks to address the challenges posed by the most difficult-to-treat cancers. Ipsen’s decades of work in oncology have generated differentiated treatments in indications with high unmet needs, including prostate cancer, breast cancer, neuroendocrine tumors, medullary thyroid cancer, differentiated thyroid cancer, hepatocellular carcinoma, renal cell carcinoma and pancreatic cancer.

Ipsen sells more than 25 medicines in over 115 countries, with a direct commercial presence in more than 30 countries.

Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.).

For more information on Ipsen, visit www.ipsen.com